Quarterly report [Sections 13 or 15(d)]

Cover

v3.25.4
Cover - shares
6 Months Ended
Jun. 30, 2025
Aug. 08, 2025
Cover [Abstract]    
Document Type 10-Q/A  
Amendment Flag true  
Amendment Description GT Biopharma, Inc. (the “Company”) is filing this Quarterly Report on Form 10-Q/A, Amendment No. 1 (the “Quarterly Report on Form 10-Q/A”) to amend and restate its Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2025 filed with the Securities and Exchange Commission on May 15, 2025 (the “Original Report”). The purpose of this Quarterly Report on Form 10-Q/A is to restate the Company’s balance sheet, statement of operations, and statement of cash flows to correct of material errors as indicated below.  
Document Quarterly Report true  
Document Transition Report false  
Document Period End Date Jun. 30, 2025  
Document Fiscal Period Focus Q2  
Document Fiscal Year Focus 2025  
Current Fiscal Year End Date --12-31  
Entity File Number 001-40023  
Entity Registrant Name GT BIOPHARMA, INC.  
Entity Central Index Key 0000109657  
Entity Tax Identification Number 94-1620407  
Entity Incorporation, State or Country Code DE  
Entity Address, Address Line One 505 Montgomery Street  
Entity Address, Address Line Two 10th Floor  
Entity Address, City or Town San Francisco  
Entity Address, State or Province CA  
Entity Address, Postal Zip Code 94111  
City Area Code 415  
Local Phone Number 919-4040  
Title of 12(b) Security Common Stock, $0.001 par value per share  
Trading Symbol GTBP  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   3,557,502